| 摘要 |
Described is a novel ophthalmic product, which is topically applied and which formulation is based on pazufloxacin as active ingredient; the invention is prescribed in infectious processes of the palpebral and bulbar conjuntiva, cornea and anterior eye segment, in chronic anterior uveitis, corneal damage and as a prophylactic treatment of post-surgical inflammation and infection.
|
